SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alkem Laboratories - Quaterly Results

12 Nov 2021 Evaluate
The Revenue for the quarter ended  September 2021 of Rs. 23639.90 millions grew by 19.15 % from Rs. 19841.00 millions.Net profit stood at Rs. 5580.10  millions  compared to Rs. 4952.00 millions in the corresponding previous quarter,high by 12.68%.Operating profit surged to 6310.50 millions from the corresponding previous quarter of 6191.10 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202109 202009 % Var 202109 202009 % Var 202103 202003 % Var
Sales 23639.90 19841.00 19.15 46426.60 35234.60 31.76 72196.80 66770.80 8.13
Other Income 432.10 248.40 73.95 824.20 687.80 19.83 1900.10 959.80 97.97
PBIDT 6310.50 6191.10 1.93 12208.30 11581.30 5.41 21389.40 15636.30 36.79
Interest 85.00 147.60 -42.41 175.60 268.00 -34.48 429.30 387.10 10.90
PBDT 6225.50 6043.50 3.01 12032.70 11313.30 6.36 20832.30 15249.20 36.61
Depreciation 538.20 516.20 4.26 1055.40 994.70 6.10 1989.30 1868.40 6.47
PBT 5687.30 5527.30 2.89 10977.30 10318.60 6.38 18843.00 13380.80 40.82
TAX 107.20 575.30 -81.37 704.50 1105.00 -36.24 1992.20 736.60 170.46
Deferred Tax -882.40 -399.60 120.82 -1201.30 -703.20 70.83 -1326.10 -1732.90 -23.48
PAT 5580.10 4952.00 12.68 10272.80 9213.60 11.50 16850.80 12644.20 33.27
Equity 239.10 239.10 0.00 239.10 239.10 0.00 239.10 239.10 0.00
PBIDTM(%) 26.69 31.20 -14.45 26.30 32.87 -20.00 29.63 23.42 26.51

Alkem Laboratories Share Price

5583.70 16.00 (0.29%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×